Source: https://maps.cancer.gov/overview/DCCPSGrants/abstract.jsp?applId=9437745&term=CA176785
Timestamp: 2019-04-24 05:12:03+00:00

Document:
DESCRIPTION (provided by applicant): Breast cancer is one of the most common cancers in the US with approximately 227,000 new cases of invasive breast cancer and 40,000 breast cancer deaths predicted in 2012. Breast cancer has a strong heritable component with approximately 15% to 20% of cases exhibiting a family history of the disease. Susceptibility to breast cancer is associated with rare germline variants in high-risk genes such as BRCA1 and BRCA2, several intermediate-risk (3 to 5 fold) predisposition genes such as PALB2 and CHEK2, and many common genetic variants associated with modest (<1.5 fold) increased risk of disease. Currently, high-risk genes and intermediate risk genes are used for clinical genetic testing for breast cancer susceptibility and for clinical management of individuals with a family history of breast cancer. However, the known predisposing variants account for less than 50% of all familial breast cancer cases. Thus, many individuals with a family history of breast cancer cannot benefit from informative clinical genetic testing and enhanced cancer risk assessment and management. Although non-genetic factors and additional common genetic variants also may influence breast cancer risk, it is unlikely that these additional factors account for all of te missing heritability of breast cancer. Thus, we hypothesize that a significant amount of the unexplained familial risk of breast cancer is due to rare genetic variants that are associated with intermediate-to-high risk. Herein, we propose to identify and characterize novel breast cancer susceptibility genes using a comprehensive sequence-based approach. We have already completed whole exome sequencing of multiple germline DNA samples from 200 high-risk breast cancer families and now propose to leverage the results from these exome sequencing studies to establish the contribution of candidate variants and genes to breast cancer. In Aim 1, we will validate 400 candidate genes in a case-control study of 4,000 familial breast cancer cases and 4,000 unaffected controls. In Aim 2 we will take a different approach to the identification of breast cancer risk factors by evaluating associations between rare recurring protein-coding variants and breast cancer risk. We will use a large case-control study of 8,000 breast cancer cases and 8,000 matched unaffected controls to validate candidates. Finally, in Aim 3 we will conduct functional studies of the candidate genes and variants from Aims 1 and 2 in order to improve prediction of pathogenic and non-pathogenic variants for the validation studies and to understand the signaling mechanisms associated with predisposition to breast cancer. The research team involved in this project has access to large, well annotated patient resources, has an established background in this research, is leveraging extensive preliminary data, and has the ability to utilize the findings for the benefit of breast cancer patients. Thus, his team is well positioned to account for much of the "missing heritability" of breast cancer.
Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
Authors: Hart S.N. , Hoskin T. , Shimelis H. , Moore R.M. , Feng B. , Thomas A. , Lindor N.M. , Polley E.C. , Goldgar D.E. , Iversen E. , et al. .
Source: Genetics In Medicine : Official Journal Of The American College Of Medical Genetics, 2018-06-08 00:00:00.0; , .
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
Authors: Rebbeck T.R. , Friebel T.M. , Friedman E. , Hamann U. , Huo D. , Kwong A. , Olah E. , Olopade O.I. , Solano A.R. , Teo S.H. , et al. .
Source: Human Mutation, 2018 May; 39(5), p. 593-620.
E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.
Authors: Horne H.N. , Oh H. , Sherman M.E. , Palakal M. , Hewitt S.M. , Schmidt M.K. , Milne R.L. , Hardisson D. , Benitez J. , Blomqvist C. , et al. .
Source: Scientific Reports, 2018-04-26 00:00:00.0; 8(1), p. 6574.
Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future.
Authors: Lilyquist J. , Ruddy K.J. , Vachon C.M. , Couch F.J. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2018 Apr; 27(4), p. 380-394.
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.
Authors: Milne R.L. , Kuchenbaecker K.B. , Michailidou K. , Beesley J. , Kar S. , Lindström S. , Hui S. , Lemaçon A. , Soucy P. , Dennis J. , et al. .
Source: Nature Genetics, 2017 Dec; 49(12), p. 1767-1778.
Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
Authors: Brouckaert O. , Rudolph A. , Laenen A. , Keeman R. , Bolla M.K. , Wang Q. , Soubry A. , Wildiers H. , Andrulis I.L. , Arndt V. , et al. .
Source: Breast Cancer Research : Bcr, 2017-11-07 00:00:00.0; 19(1), p. 119.
Association analysis identifies 65 new breast cancer risk loci.
Authors: Michailidou K. , Lindström S. , Dennis J. , Beesley J. , Hui S. , Kar S. , Lemaçon A. , Soucy P. , Glubb D. , Rostamianfar A. , et al. .
Source: Nature, 2017-11-02 00:00:00.0; 551(7678), p. 92-94.
Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.
Authors: Barrdahl M. , Rudolph A. , Hopper J.L. , Southey M.C. , Broeks A. , Fasching P.A. , Beckmann M.W. , Gago-Dominguez M. , Castelao J.E. , Guénel P. , et al. .
Source: International Journal Of Cancer, 2017-11-01 00:00:00.0; 141(9), p. 1830-1840.
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
Authors: Lecarpentier J. , Silvestri V. , Kuchenbaecker K.B. , Barrowdale D. , Dennis J. , McGuffog L. , Soucy P. , Leslie G. , Rizzolo P. , Navazio A.S. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2017-07-10 00:00:00.0; 35(20), p. 2240-2250.
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Authors: Kuchenbaecker K.B. , McGuffog L. , Barrowdale D. , Lee A. , Soucy P. , Dennis J. , Domchek S.M. , Robson M. , Spurdle A.B. , Ramus S.J. , et al. .
Source: Journal Of The National Cancer Institute, 2017-07-01 00:00:00.0; 109(7), .
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Authors: Phelan C.M. , Kuchenbaecker K.B. , Tyrer J.P. , Kar S.P. , Lawrenson K. , Winham S.J. , Dennis J. , Pirie A. , Riggan M.J. , Chornokur G. , et al. .
Source: Nature Genetics, 2017 May; 49(5), p. 680-691.
Authors: Walker L.C. , Marquart L. , Pearson J.F. , Wiggins G.A. , O'Mara T.A. , Parsons M.T. , BCFR , Barrowdale D. , McGuffog L. , Dennis J. , et al. .
Source: European Journal Of Human Genetics : Ejhg, 2017 Apr; 25(4), p. 432-438.
TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.
Authors: Fagerholm R. , Khan S. , Schmidt M.K. , García-Closas M. , Heikkilä P. , Saarela J. , Beesley J. , Jamshidi M. , Aittomäki K. , Liu J. , et al. .
Source: Oncotarget, 2017-03-14 00:00:00.0; 8(11), p. 18381-18398.
Authors: Shimelis H. , Mesman R.L. , Von Nicolai C. , Ehlen A. , Guidugli L. , Martin C. , Calleja F.M. , Meeks H. , Hallberg E. , Hinton J. , et al. .
Source: Cancer Research, 2017-03-10 00:00:00.0; , .
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.
Authors: Slavin T.P. , Maxwell K.N. , Lilyquist J. , Vijai J. , Neuhausen S.L. , Hart S.N. , Ravichandran V. , Thomas T. , Maria A. , Villano D. , et al. .
Source: Npj Breast Cancer, 2017; 3, p. 22.
Authors: Pritzlaff M. , Summerour P. , McFarland R. , Li S. , Reineke P. , Dolinsky J.S. , Goldgar D.E. , Shimelis H. , Couch F.J. , Chao E.C. , et al. .
Source: Breast Cancer Research And Treatment, 2016-12-22 00:00:00.0; , .
Authors: Hamdi Y. , Soucy P. , Adoue V. , Michailidou K. , Canisius S. , Lemaçon A. , Droit A. , Andrulis I.L. , Anton-Culver H. , Arndt V. , et al. .
Source: Oncotarget, 2016-12-06 00:00:00.0; 7(49), p. 80140-80163.
Authors: Malkov S. , Shepherd J.A. , Scott C.G. , Tamimi R.M. , Ma L. , Bertrand K.A. , Couch F. , Jensen M.R. , Mahmoudzadeh A.P. , Fan B. , et al. .
Source: Breast Cancer Research : Bcr, 2016-12-06 00:00:00.0; 18(1), p. 122.
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
Authors: Southey M.C. , Goldgar D.E. , Winqvist R. , Pylkäs K. , Couch F. , Tischkowitz M. , Foulkes W.D. , Dennis J. , Michailidou K. , van Rensburg E.J. , et al. .
Source: Journal Of Medical Genetics, 2016 Dec; 53(12), p. 800-811.
Authors: Liu J. , Lon¿ar I. , Collée J.M. , Bolla M.K. , Dennis J. , Michailidou K. , Wang Q. , Andrulis I.L. , Barile M. , Beckmann M.W. , et al. .
Source: Scientific Reports, 2016-11-15 00:00:00.0; 6, p. 36874.
Authors: Rebbeck T.R. , Friebel T.M. , Mitra N. , Wan F. , Chen S. , Andrulis I.L. , Apostolou P. , Arnold N. , Arun B.K. , Barrowdale D. , et al. .
Source: Breast Cancer Research : Bcr, 2016-11-11 00:00:00.0; 18(1), p. 112.
Authors: Catucci I. , Radice P. , Milne R.L. , Couch F.J. , Southey M.C. , Peterlongo P. .
Source: Breast Cancer Research : Bcr, 2016-11-09 00:00:00.0; 18(1), p. 111.
Authors: Vijai J. , Topka S. , Villano D. , Ravichandran V. , Maxwell K.N. , Maria A. , Thomas T. , Gaddam P. , Lincoln A. , Kazzaz S. , et al. .
Source: Cancer Discovery, 2016 Nov; 6(11), p. 1267-1275.
Authors: Hamdi Y. , Soucy P. , Kuchenbaeker K.B. , Pastinen T. , Droit A. , Lemaçon A. , Adlard J. , Aittomäki K. , Andrulis I.L. , Arason A. , et al. .
Source: Breast Cancer Research And Treatment, 2016-10-28 00:00:00.0; , .
Authors: Ghoussaini M. , French J.D. , Michailidou K. , Nord S. , Beesley J. , Canisus S. , Hillman K.M. , Kaufmann S. , Sivakumaran H. , Moradi Marjaneh M. , et al. .
Source: American Journal Of Human Genetics, 2016-10-06 00:00:00.0; 99(4), p. 903-911.
Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
Authors: Muranen T.A. , Greco D. , Blomqvist C. , Aittomäki K. , Khan S. , Hogervorst F. , Verhoef S. , Pharoah P.D. , Dunning A.M. , Shah M. , et al. .
Source: Genetics In Medicine : Official Journal Of The American College Of Medical Genetics, 2016-10-06 00:00:00.0; , .
Authors: Muranen T.A. , Blomqvist C. , Dörk T. , Jakubowska A. , Heikkilä P. , Fagerholm R. , Greco D. , Aittomäki K. , Bojesen S.E. , Shah M. , et al. .
Source: Breast Cancer Research : Bcr, 2016-10-03 00:00:00.0; 18(1), p. 98.
Authors: Darabi H. , Beesley J. , Droit A. , Kar S. , Nord S. , Moradi Marjaneh M. , Soucy P. , Michailidou K. , Ghoussaini M. , Fues Wahl H. , et al. .
Source: Scientific Reports, 2016-09-07 00:00:00.0; 6, p. 32512.
Authors: Lawrenson K. , Kar S. , McCue K. , Kuchenbaeker K. , Michailidou K. , Tyrer J. , Beesley J. , Ramus S.J. , Li Q. , Delgado M.K. , et al. .
Source: Nature Communications, 2016-09-07 00:00:00.0; 7, p. 12675.
Authors: Wyszynski A. , Hong C.C. , Lam K. , Michailidou K. , Lytle C. , Yao S. , Zhang Y. , Bolla M.K. , Wang Q. , Dennis J. , et al. .
Source: Human Molecular Genetics, 2016-09-01 00:00:00.0; 25(17), p. 3863-3876.
Authors: Kar S.P. , Beesley J. , Amin Al Olama A. , Michailidou K. , Tyrer J. , Kote-Jarai Z. , Lawrenson K. , Lindstrom S. , Ramus S.J. , Thompson D.J. , et al. .
Source: Cancer Discovery, 2016 Sep; 6(9), p. 1052-67.
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
Authors: Schmidt M.K. , Hogervorst F. , van Hien R. , Cornelissen S. , Broeks A. , Adank M.A. , Meijers H. , Waisfisz Q. , Hollestelle A. , Schutte M. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2016-08-10 00:00:00.0; 34(23), p. 2750-60.
Authors: Guo Y. , Warren Andersen S. , Shu X.O. , Michailidou K. , Bolla M.K. , Wang Q. , Garcia-Closas M. , Milne R.L. , Schmidt M.K. , Chang-Claude J. , et al. .
Source: Plos Medicine, 2016 Aug; 13(8), p. e1002105.
Authors: Zeng C. , Guo X. , Long J. , Kuchenbaecker K.B. , Droit A. , Michailidou K. , Ghoussaini M. , Kar S. , Freeman A. , Hopper J.L. , et al. .
Source: Breast Cancer Research : Bcr, 2016-06-21 00:00:00.0; 18(1), p. 64.
Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
Authors: Maxwell K.N. , Hart S.N. , Vijai J. , Schrader K.A. , Slavin T.P. , Thomas T. , Wubbenhorst B. , Ravichandran V. , Moore R.M. , Hu C. , et al. .
Source: American Journal Of Human Genetics, 2016-05-05 00:00:00.0; 98(5), p. 801-17.
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
Authors: Easton D.F. , Lesueur F. , Decker B. , Michailidou K. , Li J. , Allen J. , Luccarini C. , Pooley K.A. , Shah M. , Bolla M.K. , et al. .
Source: Journal Of Medical Genetics, 2016 May; 53(5), p. 298-309.
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.
Authors: Couch F.J. , Kuchenbaecker K.B. , Michailidou K. , Mendoza-Fandino G.A. , Nord S. , Lilyquist J. , Olswold C. , Hallberg E. , Agata S. , Ahsan H. , et al. .
Source: Nature Communications, 2016-04-27 00:00:00.0; 7, p. 11375.
Authors: Dunning A.M. , Michailidou K. , Kuchenbaecker K.B. , Thompson D. , French J.D. , Beesley J. , Healey C.S. , Kar S. , Pooley K.A. , Lopez-Knowles E. , et al. .
Source: Nature Genetics, 2016 Apr; 48(4), p. 374-86.
Genetic predisposition to ductal carcinoma in situ of the breast.
Authors: Petridis C. , Brook M.N. , Shah V. , Kohut K. , Gorman P. , Caneppele M. , Levi D. , Papouli E. , Orr N. , Cox A. , et al. .
Source: Breast Cancer Research : Bcr, 2016-02-17 00:00:00.0; 18(1), p. 22.
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
Authors: Silvestri V. , Barrowdale D. , Mulligan A.M. , Neuhausen S.L. , Fox S. , Karlan B.Y. , Mitchell G. , James P. , Thull D.L. , Zorn K.K. , et al. .
Source: Breast Cancer Research : Bcr, 2016-02-09 00:00:00.0; 18(1), p. 15.
Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
Authors: Sung H. , Garcia-Closas M. , Chang-Claude J. , Blows F.M. , Ali H.R. , Figueroa J. , Nevanlinna H. , Fagerholm R. , Heikkilä P. , Blomqvist C. , et al. .
Source: British Journal Of Cancer, 2016-02-02 00:00:00.0; 114(3), p. 298-304.
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
Authors: Meeks H.D. , Song H. , Michailidou K. , Bolla M.K. , Dennis J. , Wang Q. , Barrowdale D. , Frost D. , EMBRACE , McGuffog L. , et al. .
Source: Journal Of The National Cancer Institute, 2016 Feb; 108(2), .
Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium.
Authors: Lei J. , Rudolph A. , Moysich K.B. , Behrens S. , Goode E.L. , Bolla M.K. , Dennis J. , Dunning A.M. , Easton D.F. , Wang Q. , et al. .
Source: Human Genetics, 2016 Jan; 135(1), p. 137-54.
Genomic Biomarkers for Breast Cancer Risk.
Authors: Walsh M.F. , Nathanson K.L. , Couch F.J. , Offit K. .
Source: Advances In Experimental Medicine And Biology, 2016; 882, p. 1-32.
RAD51B in Familial Breast Cancer.
Authors: Pelttari L.M. , Khan S. , Vuorela M. , Kiiski J.I. , Vilske S. , Nevanlinna V. , Ranta S. , Schleutker J. , Winqvist R. , Kallioniemi A. , et al. .
Source: Plos One, 2016; 11(5), p. e0153788.
Authors: Horne H.N. , Chung C.C. , Zhang H. , Yu K. , Prokunina-Olsson L. , Michailidou K. , Bolla M.K. , Wang Q. , Dennis J. , Hopper J.L. , et al. .
Source: Plos One, 2016; 11(8), p. e0160316.
SNP-SNP interaction analysis of NF-¿B signaling pathway on breast cancer survival.
Authors: Jamshidi M. , Fagerholm R. , Khan S. , Aittomäki K. , Czene K. , Darabi H. , Li J. , Andrulis I.L. , Chang-Claude J. , Devilee P. , et al. .
Source: Oncotarget, 2015-11-10 00:00:00.0; 6(35), p. 37979-94.
Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization.
Authors: Zhang B. , Shu X.O. , Delahanty R.J. , Zeng C. , Michailidou K. , Bolla M.K. , Wang Q. , Dennis J. , Wen W. , Long J. , et al. .
Source: Journal Of The National Cancer Institute, 2015 Nov; 107(11), .
Authors: Peterlongo P. , Catucci I. , Colombo M. , Caleca L. , Mucaki E. , Bogliolo M. , Marin M. , Damiola F. , Bernard L. , Pensotti V. , et al. .
Source: Human Molecular Genetics, 2015-09-15 00:00:00.0; 24(18), p. 5345-55.
Authors: Hart S.N. , Maxwell K.N. , Thomas T. , Ravichandran V. , Wubberhorst B. , Klein R.J. , Schrader K. , Szabo C. , Weitzel J.N. , Neuhausen S.L. , et al. .
Source: Briefings In Bioinformatics, 2015-09-10 00:00:00.0; , .

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.